Amylin Pharmaceuticals (AMLN) 10% Owner, Black Bear Offshore Master Fund, Buys 894K Shares
More News related to AMLN
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
- Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
- Notable Analyst Rating Changes 6/9: MVSN, MUR, ETN Upgraded; AMLN, LL, FTO Downgraded
- Pre-Open Movers 06/09: Hilb Rogal & Hobbs (HRH) Surges on Buy, Lehman (LEH) Weak After Massive Loss/Capital Raise
Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) 10% beneficial owner, Black Bear Offshore Master Fund, purchased 894,000 shares of Amylin on 4/21 at prices ranging from $28.52-$29.55, bringing its stake to 15,674,698 shares.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. [BCS]
Related Categories
Insider TradesStocks Mentioned
-0.89Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
